Oramed Pharmaceuticals Inc. (ORMP) Social Stream



Oramed Pharmaceuticals Inc. (ORMP): $4.50

-0.06 (-1.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORMP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 397

in industry

Featured Post From StockTwits About ORMP

$ORMP For what it's worth, here's the company's response:

"The recent sale of shares by the CEO was triggered automatically, based on a plan that had been put in place previously and is solely dependent on stock price (and not events). It’s not possible to know when that stock price would be reached in advance.

[I should also note that although the CEO reduced the shares he was granted when he founded Oramed, he has been granted additional restricted shares and options over the years and therefore, the sale actually represents a smaller percentage of his overall holdings.]

Oramed is continuing on its Phase 3 clinical trials of oral insulin – the first ever under and FDA protocol – and Oravax Medical, of which Oramed is majority shareholder, will soon begin clinical trials of its oral Covid-19 vaccine."
Schwarzy, published August 13, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3424 seconds.